These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 1982840)

  • 21. Transfer of native insulin through the peritoneal membrane during CAPD in non-diabetic and diabetic patients.
    Ersoy FF; Karayalcin U; Karayalcin B; Sapan M; Bozcuk H; Süleymanlar G; Yakupoglu G
    Adv Perit Dial; 1995; 11():119-22. PubMed ID: 8534683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutritional parameters in diabetic patients on CAPD.
    Scanziani R; Dozio B; Bonforte G; Surian M
    Adv Perit Dial; 1996; 12():280-3. PubMed ID: 8865919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parathyroid hormone contributes to variations in blood morphology in diabetic and non diabetic patients treated with continuous ambulatory peritoneal dialysis.
    Grzegorzewska AE; Mariak I
    Adv Perit Dial; 2001; 17():5-9. PubMed ID: 11510296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum leptin, resistin, and lipid levels in patients with end stage renal failure with regard to dialysis modality.
    Taskapan MC; Taskapan H; Sahin I; Keskin L; Atmaca H; Ozyalin F
    Ren Fail; 2007; 29(2):147-54. PubMed ID: 17365928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of therapeutic efficacy of continuous ambulatory peritoneal dialysis between diabetic and non-diabetic patients: three years of experience.
    Tsai TJ; Tsai HF; Wu MS; Chuang CM; Chen WY
    Taiwan Yi Xue Hui Za Zhi; 1989 Oct; 88(10):1000-7. PubMed ID: 2699488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1% amino acid peritoneal dialysate: single-cycle study in diabetic patients with end-stage renal disease.
    Arfeen S; Goodship TH; Kirkwood A; Channon S; Ward MK
    Am J Kidney Dis; 1994 Jan; 23(1):86-90. PubMed ID: 8285202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Endothelial dysfunction in uremic patients on continuous ambulatory peritoneal dialysis (CAPD).
    Rašić S; Hadžović-Džuvo A; Rebić D; Valjevac A; Unčanin S
    Bosn J Basic Med Sci; 2011 Aug; 11(3):153-7. PubMed ID: 21875416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): an in vivo model for the study of diabetic microangiopathy.
    Di Paolo N; Sacchi G
    Perit Dial Int; 1989; 9(1):41-5. PubMed ID: 2488179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAPD with an amino acid dialysis solution: a long-term, cross-over study.
    Bruno M; Bagnis C; Marangella M; Rovera L; Cantaluppi A; Linari F
    Kidney Int; 1989 May; 35(5):1189-94. PubMed ID: 2770103
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual function, blood pressure and blood glucose in diabetic patients undergoing continuous ambulatory peritoneal dialysis.
    Rottembourg J; Bellio P; Maiga K; Remaoun M; Rousselie F; Legrain M
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():330-4. PubMed ID: 3991520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of the uremic diabetic.
    Shyh TP; Beyer MM; Friedman EA
    Nephron; 1985; 40(2):129-38. PubMed ID: 3889674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of intraperitoneal infusion of dextrose and amino acids on the appetite of rabbits.
    Balaskas EV; Rodela H; Oreopoulos DG
    Perit Dial Int; 1993; 13 Suppl 2():S490-8. PubMed ID: 8399648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin therapy in uremic diabetic patients on continuous ambulatory peritoneal dialysis; comparison of intraperitoneal and subcutaneous administration.
    Scarpioni L; Ballocchi S; Castelli A; Scarpioni R
    Perit Dial Int; 1994; 14(2):127-31. PubMed ID: 8043664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intermediary metabolism and glycemic control in insulin-dependent diabetic uremic patients treated by continuous peritoneal dialysis.
    Spotti D; Slaviero G; La Rocca E; Cantaluppi A; Castelnovo C; Micossi P; Quartagno R; Melandri M; Pozza G; Ponticelli C
    Nephron; 1988; 49(3):219-22. PubMed ID: 3041295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute metabolic effects of dialysis fluids during CAPD.
    Delarue J; Maingourd C
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S103-7. PubMed ID: 11158872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of an amino-acid-based CAPD fluid over 12 weeks.
    Young GA; Dibble JB; Hobson SM; Tompkins L; Gibson J; Turney JH; Brownjohn AM
    Nephrol Dial Transplant; 1989; 4(4):285-92. PubMed ID: 2502736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on amino acids in diabetic patients undergoing CAPD.
    Giordano C; De Santo NG; Capodicasa G; Di Serafino A; Di Leo VA; Fiore R; Damiano M; Buonadonna L; Iorio B
    Int J Artif Organs; 1981 Mar; 4(2):62-7. PubMed ID: 7275336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum advanced glycosylation end products: a new class of uremic toxins?
    Vlassara H
    Blood Purif; 1994; 12(1):54-9. PubMed ID: 7986476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Malnutrition in continuous ambulatory peritoneal dialysis and use of intraperitoneal amino acids.
    Dombros NV; Digenis GE; Oreopoulos DG
    Contrib Nephrol; 1992; 100():188-206. PubMed ID: 1458902
    [No Abstract]   [Full Text] [Related]  

  • 40. Hemofiltration in diabetic uremic patients.
    Segoloni GP; Pacitti A; Squiccimarro G; Triolo G; Ragni R; Vercellone A; Civati G; Guastoni C; Perego A; Teatini U; Minetti L; Carta Q
    Int J Artif Organs; 1983 Jan; 6(1):15-9. PubMed ID: 6341257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.